{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T22:02:34Z","timestamp":1764540154515,"version":"build-2065373602"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.clml.2016.02.013","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T10:08:18Z","timestamp":1470737298000},"page":"S74-S81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"S","title":["Treatment of Chronic Lymphocytic Leukemia With del(17p)\/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?"],"prefix":"10.1016","volume":"16","author":[{"given":"Emili","family":"Montserrat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2016.02.013_bib1","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1182\/blood-2009-04-214346","article-title":"Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience","volume":"114","author":"Abrisqueta","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib2","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2007-12-129379","article-title":"Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib3","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3324\/haematol.2009.007849","article-title":"Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden","volume":"94","author":"Kristinsson","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.02.013_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2014.115923","article-title":"Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution","volume":"100","author":"Sutton","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.02.013_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-pathol-020712-163955","article-title":"The pathogenesis of chronic lymphocytic leukemia","volume":"9","author":"Zhang","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.clml.2016.02.013_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semcancer.2013.08.011","article-title":"The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies","volume":"24","author":"Burger","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.clml.2016.02.013_bib7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.semcancer.2010.10.012","article-title":"New insights into the pathogenesis of chronic lymphocytic leukemia","volume":"20","author":"Klein","year":"2010","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.clml.2016.02.013_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc2764","article-title":"From pathogenesis to treatment of chronic lymphocytic leukaemia","volume":"10","author":"Zenz","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2016.02.013_bib9","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","article-title":"p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias","volume":"85","author":"D\u00f6hner","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib10","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.02.013_bib11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/ejh.12106","article-title":"The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab","volume":"90","author":"Panovska","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2016.02.013_bib12","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2014-06-583765","article-title":"Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)","volume":"124","author":"Tam","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.23999","article-title":"Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience","volume":"90","author":"Fornecker","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2016.02.013_bib14","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2013-09-453092","article-title":"How will B-cell-receptor-targeted therapies change future CLL therapy?","volume":"123","author":"Jones","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib15","first-page":"1","article-title":"How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and\/or TP53 mutation?","volume":"8194","author":"Tam","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2016.02.013_bib16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ajh.24021","article-title":"Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors","volume":"90","author":"Mato","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2016.02.013_bib17","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.02.013_bib18","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood-2009-05-224071","article-title":"Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial","volume":"114","author":"Zenz","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib19","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1078-0432.CCR-08-1630","article-title":"The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of del17p13: implications for overall survival and chemorefractoriness","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2016.02.013_bib20","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/leu.2012.25","article-title":"ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia","volume":"26","author":"Pospisilova","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.02.013_bib21","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1182\/blood-2012-05-433540","article-title":"Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns","volume":"120","author":"Schuh","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib22","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/leu.2014.297","article-title":"Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia","volume":"29","author":"Malcikova","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.02.013_bib23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/leu.2013.248","article-title":"Clonal evolution in hematological malignancies and therapeutic implications","volume":"28","author":"Landau","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.02.013_bib24","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3324\/haematol.2012.069369","article-title":"Clinical implications of the molecular genetics of chronic lymphocytic leukemia","volume":"98","author":"Fo\u00e0","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.02.013_bib25","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1200\/JCO.2010.32.0838","article-title":"Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial","volume":"29","author":"Gonzalez","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.02.013_bib26","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/CCO.0b013e328331b702","article-title":"Genetic lesions in chronic lymphocytic leukemia: clinical implications","volume":"21","author":"Montserrat","year":"2009","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clml.2016.02.013_bib27","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2009-03-210591","article-title":"De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience","volume":"114","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.2011.09000.x","article-title":"Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results","volume":"157","author":"Delgado","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.02.013_bib29","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib30","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1002\/cncr.29566","article-title":"Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens","volume":"121","author":"Thompson","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2016.02.013_bib31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.leu.2404441","article-title":"Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus","volume":"21","author":"Dreger","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.02.013_bib32","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/annonc\/mdt511","article-title":"The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison","volume":"25","author":"Herth","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2016.02.013_bib33","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1200\/JCO.2005.04.531","article-title":"Allogeneic stem cell transplantation may overcome the adverse prognosis of unmutated IGHV gene in patients with chronic lymphocytic leukemia","volume":"23","author":"Moreno","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2016.02.013_bib34","doi-asserted-by":"crossref","first-page":"7757","DOI":"10.1158\/1078-0432.CCR-05-0941","article-title":"Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q\u2212 and 17p\u2212)","volume":"11","author":"Caballero","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2016.02.013_bib35","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1182\/blood-2012-11-469627","article-title":"TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial","volume":"121","author":"Dreger","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib36","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.leu.2402905","article-title":"Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning","volume":"17","author":"Dreger","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.02.013_bib37","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2002-02-0400","article-title":"Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes","volume":"100","author":"Martino","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib38","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.2003.12.011","article-title":"Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: The Cooperative German Transplant Study Group","volume":"21","author":"Schetelig","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.02.013_bib39","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/leu.2008.96","article-title":"Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial","volume":"2296","author":"Ritgen","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.02.013_bib40","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/bmt.2015.150","article-title":"Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse","volume":"50","author":"Hahn","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2016.02.013_bib41","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bbmt.2008.09.001","article-title":"The effect of in vivo T-cell depletion with alemtuzumab on reduced intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia","volume":"14","author":"Delgado","year":"2008","journal-title":"Biol Bone Marrow Transpl."},{"key":"10.1016\/j.clml.2016.02.013_bib42","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2003-05-1513","article-title":"Dose-escalated donor lymphocyte infusion following reduced intensity transplantation: toxicity, chimerism, and disease response","volume":"103","author":"Peggs","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib43","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood-2010-03-275420","article-title":"Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia:long-term clinical and MRD results of the GCLLSG CLL3X trial","volume":"116","author":"Dreger","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib44","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1002\/cncr.26091","article-title":"Nonmyeloablative allogeneic stem cell transplantation in relapsed\/refractory chronic lymphocytic leukemia","volume":"117","author":"Khouri","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2016.02.013_bib45","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1200\/JCO.2008.16.2982","article-title":"Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis","volume":"26","author":"Schetelig","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.02.013_bib46","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/leu.2012.228","article-title":"Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome","volume":"27","author":"Brown","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.02.013_bib47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2141.2012.09239.x","article-title":"Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia","volume":"159","author":"Jaglowski","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.02.013_bib48","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2007.15.4757","article-title":"Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"26","author":"Sorror","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.02.013_bib49","article-title":"Allogeneic hematopoietic transplantation in patients with CLL: results of a large disease-specific risk factor analysis","volume":"124","author":"Schtelig","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib50","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1182\/blood-2014-07-586826","article-title":"Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?","volume":"124","author":"Dreger","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib51","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11899-014-0242-1","article-title":"Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia?","volume":"10","author":"Dreger","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2016.02.013_bib52","doi-asserted-by":"crossref","unstructured":"van Gelder M, van Oers M, Alemayehu WG, et\u00a0al., Activity and safety of cisplatin-based immunochemotherapy followed by allogeneic stem cell transplantation for high risk chronic lymphocytic leukemia: final results of the prospective multicenter phase 2 study HOVON88. Bone Marrow Transplant, [e-pub ahead of print]. http:\/\/dx.doi.org\/10.1038\/bmt.2016.9.","DOI":"10.1038\/bmt.2016.9"},{"key":"10.1016\/j.clml.2016.02.013_bib53","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1200\/JCO.2014.58.6750","article-title":"Outcomes of patients with chronic lymphocytic leukemia and Richter's transformation after transplantation failure","volume":"33","author":"Rozovski","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.02.013_bib54","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.2014.60.3282","article-title":"Hope for high-risk chronic lymphocytic leukemia relapsing after allogeneic stem-cell transplantation","volume":"33","author":"Montserrat","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.02.013_bib55","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.3324\/haematol.2014.119123","article-title":"The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia","volume":"100","author":"Wiestner","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.02.013_bib56","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.02.013_bib57","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.02.013_bib58","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib59","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","article-title":"Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study","volume":"15","author":"Burger","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2016.02.013_bib60","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"O'Brien","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2016.02.013_bib61","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2016.02.013_bib62","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2014-09-585869","article-title":"The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia","volume":"125","author":"Brown","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib63","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.02.013_bib64","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110d, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib65","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.02.013_bib66","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","article-title":"A\u00a0phase 2 study of idelalisib plus rituximab in treatment-na\u00efve older patients with chronic lymphocytic leukemia","volume":"126","author":"O'Brien","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib67","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.02.013_bib68","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.02.013_bib69","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2016.02.013_bib70","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib71","first-page":"77","article-title":"Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy","volume":"100","author":"Da","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.02.013_bib72","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood-2015-03-585075","article-title":"Targeted therapies in CLL: mechanisms of resistance and strategies for management","volume":"126","author":"Woyach","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib73","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1182\/blood-2014-12-619163","article-title":"Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy","volume":"125","author":"de Rooij","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib74","first-page":"9","article-title":"Ibrutinib in chronic lymphocytic leukaemia: alone or in combination?","volume":"2045","author":"Robak","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2016.02.013_bib75","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib76","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2016.02.013_bib77","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.02.013_bib78","doi-asserted-by":"crossref","first-page":"13906","DOI":"10.1073\/pnas.1409362111","article-title":"Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)","volume":"111","author":"Komarova","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2016.02.013_bib79","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1182\/blood-2014-08-592725","article-title":"Ibrutinib-na\u00efve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance","volume":"124","author":"Fam\u00e0","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V126.23.719.719","article-title":"Favorable outcomes in CLL pts with alternate kinase inhibitors following ibrutinib or idelalisib discontinuation: results from a large multi-center study","volume":"126","author":"Mato","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.013_bib81","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/j.bbmt.2011.11.018","article-title":"Novel therapies and their integration into allogeneic stem cell transplant for chronic lymphocytic leukemia","volume":"18","author":"Jaglowski","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2016.02.013_bib82","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminoncol.2016.02.001","article-title":"Chronic lymphocytic leukemia (CLL): recent progress and current challenges","author":"Woyach","year":"2016","journal-title":"Semin Oncology"},{"key":"10.1016\/j.clml.2016.02.013_bib83","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.bbmt.2014.11.097","article-title":"Safety and efficacy of ibrutinib in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) who have undergone prior allogeneic stem cell transplant","volume":"21","author":"Miklos","year":"2016","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016000689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016000689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:28:01Z","timestamp":1761870481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016000689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":83,"alternative-id":["S2152265016000689"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.02.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Chronic Lymphocytic Leukemia With del(17p)\/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}